CARGO Therapeutics will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco.
Quiver AI Summary
CARGO Therapeutics, Inc., a clinical-stage biotechnology company focused on developing next-generation cell therapies for cancer, announced its participation in the J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco. CEO Gina Chapman will present on January 13 at 10:30 a.m. PT, with a live webcast available on the company's website, along with a replay for 30 days post-event. The company is currently advancing its therapy candidate firicabtagene autoleucel (firi-cel) for patients with relapsed or refractory large B-cell lymphoma and is developing proprietary technologies aimed at improving the efficacy and safety of CAR T-cell therapies. CARGO’s innovative approach incorporates multiple therapeutic targets to enhance treatment durability and minimize resistance, aiming to provide a better outcome for patients with various B-cell malignancies. For more information, visit the CARGO Therapeutics website.
Potential Positives
- CARGO Therapeutics will participate in the prestigious 43rd Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the biotechnology sector.
- CEO Gina Chapman will present at the conference, which could strengthen investor interest and confidence in the company's direction and pipeline.
- The company's advanced CAR T-cell therapy candidate, firicabtagene autoleucel, is in a potentially pivotal Phase 2 clinical study, indicating significant progress in its development pipeline.
- CARGO’s innovative approach to CAR T-cell therapy could address major challenges faced by current treatments, positioning it favorably in the competitive oncology market.
Potential Negatives
- Participation in the conference may indicate a need for additional visibility and reassurance to investors regarding the company's progress and pipeline, possibly reflecting challenges in investor confidence.
FAQ
What is CARGO Therapeutics?
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing potentially curative cell therapies for cancer patients.
When is CARGO's presentation at the J.P. Morgan Healthcare Conference?
CARGO will present on Monday, January 13, 2025, at 10:30 a.m. PT during the conference.
How can I access CARGO's presentation?
The live webcast of the presentation can be accessed in the Investors section of CARGO’s website.
What is the focus of CARGO's current clinical programs?
CARGO is evaluating firicabtagene autoleucel, a CAR T-cell therapy for patients with relapsed or refractory large B-cell lymphoma.
What innovative technologies does CARGO Therapeutics use?
CARGO employs proprietary cell engineering platforms to enhance CAR T-cell persistence and address tumor resistance and T-cell exhaustion.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRGX Insider Trading Activity
$CRGX insiders have traded $CRGX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $CRGX stock by insiders over the last 6 months:
- GINA CHAPMAN (President & CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 10,141 shares.
- ANUP RADHAKRISHNAN (Chief Financial Officer) sold 1,600 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRGX Hedge Fund Activity
We have seen 53 institutional investors add shares of $CRGX stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,087,437 shares (+74.5%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 1,011,475 shares (+inf%) to their portfolio in Q3 2024
- VANGUARD GROUP INC added 600,211 shares (+41.1%) to their portfolio in Q3 2024
- COWEN AND COMPANY, LLC removed 554,305 shares (-100.0%) from their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 483,765 shares (-15.2%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 374,018 shares (+80.6%) to their portfolio in Q3 2024
- SIO CAPITAL MANAGEMENT, LLC added 173,860 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) --
CARGO Therapeutics, Inc
. (NASDAQ: CRGX)
, a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 13, at 10:30 a.m. PT.
Interested parties can access the live webcast for the presentation in the Investors section of CARGO’s website under
News & Events
. A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
About CARGO Therapeutics
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next- generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating firicabtagene autoleucel (firi-cel), an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical study in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO has developed proprietary cell engineering platform technologies which it leverages to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. This includes the CRG-023 program, which incorporates a novel tri-specific CAR T with CD2 co-stimulation that is designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a broad range of B-cell malignancies with the goal of providing more patients with a durable complete response. CARGO’s leadership and team have significant experience in developing, engineering, manufacturing, and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at
https://cargo-tx.com/
.
Follow us on LinkedIn:
CARGO Therapeutics
Follow us on X (Twitter):
@CARGOTx
Contacts
Media Contact:
Kimberly Muscara
kimberly@redhousecomms.com
Investor Contact:
Jessica Serra
jserra@cargo-tx.com
Laurence Watts
laurence@newstreetir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
